 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| 12» |
- ||| zeluvalimab (AMG 404) / Amgen, etevritamab (AMG 596) / Amgen
Trial termination, Combination therapy, Monotherapy: Study of AMG 596 in Patients With EGFRvIII Positive Glioblastoma (clinicaltrials.gov) - Oct 29, 2024
P1, N=30, Terminated, Sponsor: Amgen
Completed --> Terminated; Amgen business decision
- || Imdelltra (tarlatamab-dlle) / Amgen, zeluvalimab (AMG 404) / Amgen
Trial completion, Trial completion date: AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC) (clinicaltrials.gov) - Oct 23, 2024
P1, N=23, Completed, Sponsor: Amgen
Completed --> Terminated; Amgen business decision Active, not recruiting --> Completed | Trial completion date: Jan 2025 --> Sep 2024
- || Lumakras (sotorasib) / Amgen
Trial completion date, Trial primary completion date, Monotherapy: CodeBreak101: Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) (clinicaltrials.gov) - Oct 17, 2024
P1, N=1200, Recruiting, Sponsor: Amgen
Active, not recruiting --> Completed | Trial completion date: Jan 2025 --> Sep 2024 Trial completion date: Jun 2029 --> Mar 2028 | Trial primary completion date: Jan 2027 --> Apr 2026
- || Lumakras (sotorasib) / Amgen
Trial completion date, Trial primary completion date, Monotherapy: CodeBreak101: Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) (clinicaltrials.gov) - Oct 15, 2024
P1, N=1200, Recruiting, Sponsor: Amgen
Trial completion date: Jun 2029 --> Mar 2028 | Trial primary completion date: Jan 2027 --> Apr 2026 Trial completion date: Mar 2028 --> Jun 2029 | Trial primary completion date: Sep 2025 --> Jan 2027
- Imdelltra (tarlatamab-dlle) / Amgen, zeluvalimab (AMG 404) / Amgen
Phase classification: AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC) (clinicaltrials.gov) - Oct 15, 2024
P1, N=23, Active, not recruiting, Sponsor: Amgen
Trial completion date: Mar 2028 --> Jun 2029 | Trial primary completion date: Sep 2025 --> Jan 2027 Phase classification: P1b --> P1
- || Lumakras (sotorasib) / Amgen
Trial primary completion date, Monotherapy: CodeBreak101: Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) (clinicaltrials.gov) - Jul 25, 2024
P1, N=1200, Recruiting, Sponsor: Amgen
Phase classification: P1b --> P1 Trial primary completion date: Dec 2026 --> Sep 2025
- | Lumakras (sotorasib) / Amgen
Phase classification, Monotherapy: CodeBreak101: Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) (clinicaltrials.gov) - May 28, 2024
P1, N=1200, Recruiting, Sponsor: Amgen
Trial primary completion date: Dec 2026 --> Sep 2025 Phase classification: P1/2 --> P1
- || Lumakras (sotorasib) / Amgen
Trial primary completion date, Monotherapy: CodeBreak101: Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) (clinicaltrials.gov) - Apr 25, 2024
P1/2, N=1126, Recruiting, Sponsor: Amgen
Phase classification: P1/2 --> P1 Trial primary completion date: Sep 2026 --> Dec 2026
- Blincyto (blinatumomab) / Astellas, Amgen, zeluvalimab (AMG 404) / Amgen
Phase classification, Combination therapy: Blinatumomab in Combination With AMG 404 for the Treatment of Adults With Relapsed or Refractory B Cell Precursor ALL (clinicaltrials.gov) - Apr 7, 2024
P1, N=17, Completed, Sponsor: Amgen
Trial primary completion date: Sep 2026 --> Dec 2026 Phase classification: P1b --> P1
- ||| zeluvalimab (AMG 404) / Amgen
Trial completion, Metastases: AMG 404 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Dec 5, 2023
P1, N=171, Completed, Sponsor: Amgen
Phase classification: P1b --> P1 Active, not recruiting --> Completed
- || Lumakras (sotorasib) / Amgen
Trial primary completion date, Monotherapy: CodeBreak101: Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) (clinicaltrials.gov) - Nov 30, 2023
P1/2, N=1143, Recruiting, Sponsor: Amgen
Active, not recruiting --> Completed Trial primary completion date: Jun 2026 --> Sep 2026
- | Lumakras (sotorasib) / Amgen
Phase classification, Monotherapy: CodeBreak101: Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) (clinicaltrials.gov) - Nov 27, 2023
P1/2, N=1143, Recruiting, Sponsor: Amgen
Trial primary completion date: Jun 2026 --> Sep 2026 Phase classification: P1b/2 --> P1/2
- ||||| zeluvalimab (AMG 404) / Amgen, acapatamab (AMG 160) / Amgen, BeiGene
Trial termination: Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC) (clinicaltrials.gov) - Nov 7, 2023
P1/2, N=65, Terminated, Sponsor: Amgen
Active, not recruiting --> Terminated; Amgen made a business decision to discontinue all AMG 160 clinical trials. This decision is not related to safety.
- || Lumakras (sotorasib) / Amgen
Trial completion date, Monotherapy: CodeBreak101: Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) (clinicaltrials.gov) - Oct 27, 2023
P1b/2, N=1143, Recruiting, Sponsor: Amgen
This decision is not related to safety. Trial completion date: Jul 2027 --> Oct 2027
- | Imdelltra (tarlatamab-dlle) / Amgen, zeluvalimab (AMG 404) / Amgen
Trial completion date: AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC) (clinicaltrials.gov) - Oct 11, 2023
P1b, N=23, Active, not recruiting, Sponsor: Amgen
Trial completion date: Jul 2027 --> Oct 2027 Trial completion date: Jan 2026 --> Jan 2025
- || zeluvalimab (AMG 404) / Amgen, inezetamab (AMG994) / Amgen
Trial completion, Trial completion date, Combination therapy, Monotherapy, Metastases: Study of AMG 994 Monotherapy and AMG 994 and AMG 404 Combination Therapy in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Sep 22, 2023
P1, N=11, Completed, Sponsor: Amgen
Trial completion date: Jan 2026 --> Jan 2025 Active, not recruiting --> Completed | Trial completion date: Sep 2023 --> Jun 2023
- || Lumakras (sotorasib) / Amgen
Trial primary completion date, Monotherapy: CodeBreak101: Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) (clinicaltrials.gov) - Sep 7, 2023
P1b/2, N=1143, Recruiting, Sponsor: Amgen
Active, not recruiting --> Completed | Trial completion date: Sep 2023 --> Jun 2023 Trial primary completion date: Jan 2025 --> May 2026
- || Lumakras (sotorasib) / Amgen
Trial completion date, Trial primary completion date, Monotherapy: CodeBreak101: Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) (clinicaltrials.gov) - Aug 14, 2023
P1b/2, N=1143, Recruiting, Sponsor: Amgen
Trial primary completion date: Jan 2025 --> May 2026 Trial completion date: Jan 2029 --> Jul 2027 | Trial primary completion date: Jul 2026 --> Jan 2025
- | Imdelltra (tarlatamab-dlle) / Amgen, zeluvalimab (AMG 404) / Amgen
Trial completion date: AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC) (clinicaltrials.gov) - Jul 20, 2023
P1b, N=23, Active, not recruiting, Sponsor: Amgen
Trial completion date: Jan 2029 --> Jul 2027 | Trial primary completion date: Jul 2026 --> Jan 2025 Trial completion date: Aug 2025 --> Jan 2026
- | zeluvalimab (AMG 404) / Amgen, inezetamab (AMG994) / Amgen
Trial completion date, Trial primary completion date, Combination therapy, Monotherapy, Metastases: Study of AMG 994 Monotherapy and AMG 994 and AMG 404 Combination Therapy in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Jun 15, 2023
P1, N=11, Active, not recruiting, Sponsor: Amgen
Trial completion date: Aug 2025 --> Jan 2026 Trial completion date: Aug 2024 --> Sep 2023 | Trial primary completion date: Feb 2024 --> Jun 2023
- ||| zeluvalimab (AMG 404) / Amgen, acapatamab (AMG 160) / Amgen, BeiGene
Enrollment change: Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC) (clinicaltrials.gov) - May 22, 2023
P1/2, N=65, Active, not recruiting, Sponsor: Amgen
Trial completion date: Aug 2024 --> Sep 2023 | Trial primary completion date: Feb 2024 --> Jun 2023 N=136 --> 65
- || Lumakras (sotorasib) / Amgen
Trial completion date, Trial primary completion date, Monotherapy: CodeBreak101: Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) (clinicaltrials.gov) - Mar 24, 2023
P1b/2, N=1143, Recruiting, Sponsor: Amgen
N=136 --> 65 Trial completion date: Apr 2028 --> Jan 2029 | Trial primary completion date: Feb 2026 --> Jul 2026
- || zeluvalimab (AMG 404) / Amgen, acapatamab (AMG 160) / Amgen, BeiGene
Trial primary completion date: Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC) (clinicaltrials.gov) - Mar 9, 2023
P1/2, N=136, Active, not recruiting, Sponsor: Amgen
Trial completion date: Apr 2028 --> Jan 2029 | Trial primary completion date: Feb 2026 --> Jul 2026 Trial primary completion date: Jan 2023 --> Nov 2023
- || Lumakras (sotorasib) / Amgen
Trial completion date, Trial primary completion date, Monotherapy: CodeBreak101: Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) (clinicaltrials.gov) - Feb 9, 2023
P1b/2, N=1143, Recruiting, Sponsor: Amgen
Trial primary completion date: Jan 2023 --> Nov 2023 Trial completion date: Jun 2027 --> Apr 2028 | Trial primary completion date: Dec 2024 --> Feb 2026
- | zeluvalimab (AMG 404) / Amgen
Trial completion date, Metastases: AMG 404 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Jan 26, 2023
P1, N=170, Active, not recruiting, Sponsor: Amgen
Trial completion date: Jun 2027 --> Apr 2028 | Trial primary completion date: Dec 2024 --> Feb 2026 Trial completion date: Jul 2026 --> Nov 2023
- || Imdelltra (tarlatamab-dlle) / Amgen, zeluvalimab (AMG 404) / Amgen
Enrollment change: AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC) (clinicaltrials.gov) - Jan 26, 2023
P1b, N=23, Active, not recruiting, Sponsor: Amgen
Trial completion date: Jul 2026 --> Nov 2023 N=50 --> 23
- || Blincyto (blinatumomab) / Astellas, Amgen, zeluvalimab (AMG 404) / Amgen
Trial completion, Combination therapy: Blinatumomab in Combination With AMG 404 for the Treatment of Adults With Relapsed or Refractory B Cell Precursor ALL (clinicaltrials.gov) - Jan 26, 2023
P1b, N=17, Completed, Sponsor: Amgen
N=50 --> 23 Active, not recruiting --> Completed
- || Imdelltra (tarlatamab-dlle) / Amgen, zeluvalimab (AMG 404) / Amgen
Enrollment closed, Trial completion date, Trial primary completion date: AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC) (clinicaltrials.gov) - Dec 28, 2022
P1b, N=50, Active, not recruiting, Sponsor: Amgen
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial completion date: Jan 2026 --> Aug 2025 | Trial primary completion date: Dec 2023 --> Jun 2023
- || Lumakras (sotorasib) / Amgen
Trial completion date, Trial primary completion date, Monotherapy: CodeBreak101: Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) (clinicaltrials.gov) - Dec 20, 2022
P1b/2, N=1143, Recruiting, Sponsor: Amgen
Recruiting --> Active, not recruiting | Trial completion date: Jan 2026 --> Aug 2025 | Trial primary completion date: Dec 2023 --> Jun 2023 Trial completion date: Oct 2026 --> Jun 2027 | Trial primary completion date: Aug 2024 --> Dec 2024
- | zeluvalimab (AMG 404) / Amgen, acapatamab (AMG 160) / Amgen, BeiGene
Trial completion date: Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC) (clinicaltrials.gov) - Dec 8, 2022
P1/2, N=136, Active, not recruiting, Sponsor: Amgen
Trial completion date: Oct 2026 --> Jun 2027 | Trial primary completion date: Aug 2024 --> Dec 2024 Trial completion date: Jul 2025 --> Nov 2023
- | zeluvalimab (AMG 404) / Amgen, inezetamab (AMG994) / Amgen
Trial completion date, Trial primary completion date, Combination therapy, Monotherapy, Metastases: Study of AMG 994 Monotherapy and AMG 994 and AMG 404 Combination Therapy in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Nov 18, 2022
P1, N=11, Active, not recruiting, Sponsor: Amgen
Trial completion date: Jul 2025 --> Nov 2023 Trial completion date: Mar 2023 --> Aug 2024 | Trial primary completion date: Jan 2023 --> Feb 2024
- | Blincyto (blinatumomab) / Astellas, Amgen, zeluvalimab (AMG 404) / Amgen
Trial completion date, Trial primary completion date, Combination therapy: Blinatumomab in Combination With AMG 404 for the Treatment of Adults With Relapsed or Refractory B Cell Precursor ALL (clinicaltrials.gov) - Nov 10, 2022
P1b, N=17, Active, not recruiting, Sponsor: Amgen
Trial completion date: Mar 2023 --> Aug 2024 | Trial primary completion date: Jan 2023 --> Feb 2024 Trial completion date: Jun 2023 --> Jan 2023 | Trial primary completion date: Jun 2023 --> Jan 2023
- || Blincyto (blinatumomab) / Astellas, Amgen, zeluvalimab (AMG 404) / Amgen
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, Combination therapy: Blinatumomab in Combination With AMG 404 for the Treatment of Adults With Relapsed or Refractory B Cell Precursor ALL (clinicaltrials.gov) - Jul 28, 2022
P1b, N=17, Active, not recruiting, Sponsor: Amgen
Trial completion date: Jun 2023 --> Jan 2023 | Trial primary completion date: Jun 2023 --> Jan 2023 Recruiting --> Active, not recruiting | N=27 --> 17 | Trial completion date: Oct 2023 --> Jun 2023 | Trial primary completion date: Oct 2023 --> Jun 2023
- || zeluvalimab (AMG 404) / Amgen, acapatamab (AMG 160) / Amgen, BeiGene
Enrollment closed: Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC) (clinicaltrials.gov) - Jun 22, 2022
P1/2, N=136, Active, not recruiting, Sponsor: Amgen
Recruiting --> Active, not recruiting | N=27 --> 17 | Trial completion date: Oct 2023 --> Jun 2023 | Trial primary completion date: Oct 2023 --> Jun 2023 Recruiting --> Active, not recruiting
- ||| zeluvalimab (AMG 404) / Amgen, acapatamab (AMG 160) / Amgen, BeiGene
Enrollment open: Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC) (clinicaltrials.gov) - Jun 2, 2022
P1/2, N=159, Recruiting, Sponsor: Amgen
Recruiting --> Active, not recruiting Active, not recruiting --> Recruiting
- || zeluvalimab (AMG 404) / Amgen, acapatamab (AMG 160) / Amgen, BeiGene
Enrollment closed: Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC) (clinicaltrials.gov) - Jun 2, 2022
P1/2, N=159, Active, not recruiting, Sponsor: Amgen
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting
- || zeluvalimab (AMG 404) / Amgen, inezetamab (AMG994) / Amgen
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Monotherapy, Metastases: Study of AMG 994 Monotherapy and AMG 994 and AMG 404 Combination Therapy in Participants With Advanced Solid Tumors (clinicaltrials.gov) - May 11, 2022
P1, N=11, Active, not recruiting, Sponsor: Amgen
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | N=214 --> 11 | Trial completion date: Aug 2025 --> Mar 2023 | Trial primary completion date: Feb 2025 --> Jan 2023
- Blincyto (blinatumomab) / Astellas, Amgen, zeluvalimab (AMG 404) / Amgen
A phase 1b study of blinatumomab with the anti-programmed cell death (PD)-1 antibody AMG 404 in adults with relapsed/refractory (R/R) B-cell precursor acute lymphoblastic leukemia (ALL). () - Apr 28, 2022 - Abstract #ASCO2022ASCO_4347;
P1b
No DLTs were reported. Enrollment continues in Cohort 2 in which AMG 404 is dosed Q4W at 480 mg starting on C1D1, 48 hours prior to blinatumomab.
- || Lumakras (sotorasib) / Amgen
Trial completion date, Trial primary completion date, Monotherapy: CodeBreak101: Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) (clinicaltrials.gov) - Apr 14, 2022
P1b/2, N=1054, Recruiting, Sponsor: Amgen
Enrollment continues in Cohort 2 in which AMG 404 is dosed Q4W at 480 mg starting on C1D1, 48 hours prior to blinatumomab. Trial completion date: Jan 2027 --> Aug 2026 | Trial primary completion date: Jan 2024 --> Aug 2024
- || zeluvalimab (AMG 404) / Amgen, inezetamab (AMG994) / Amgen
Trial primary completion date, Combination therapy, Monotherapy, Metastases: Study of AMG 994 Monotherapy and AMG 994 and AMG 404 Combination Therapy in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Apr 8, 2022
P1, N=214, Recruiting, Sponsor: Amgen
Trial completion date: Jan 2027 --> Aug 2026 | Trial primary completion date: Jan 2024 --> Aug 2024 Trial primary completion date: Aug 2025 --> Feb 2025
- | Imdelltra (tarlatamab-dlle) / Amgen, zeluvalimab (AMG 404) / Amgen
Trial completion date, Trial primary completion date: AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC) (clinicaltrials.gov) - Mar 11, 2022
P1b, N=50, Recruiting, Sponsor: Amgen
Trial primary completion date: Aug 2025 --> Feb 2025 Trial completion date: Mar 2024 --> Oct 2025 | Trial primary completion date: May 2023 --> Aug 2023
- | Imdelltra (tarlatamab-dlle) / Amgen, zeluvalimab (AMG 404) / Amgen
Trial completion date: AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC) (clinicaltrials.gov) - Feb 21, 2022
P1b, N=50, Recruiting, Sponsor: Amgen
Trial completion date: Mar 2024 --> Oct 2025 | Trial primary completion date: May 2023 --> Aug 2023 Trial completion date: Mar 2025 --> Mar 2024
- || zeluvalimab (AMG 404) / Amgen
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, Metastases: AMG 404 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Feb 8, 2022
P1, N=170, Active, not recruiting, Sponsor: Amgen
Trial completion date: Mar 2025 --> Mar 2024 Recruiting --> Active, not recruiting | N=275 --> 170 | Trial completion date: Jul 2025 --> Jul 2026 | Trial primary completion date: Jul 2023 --> Jul 2022
- || zeluvalimab (AMG 404) / Amgen
Trial completion date, Trial primary completion date, Metastases: AMG 404 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Jan 11, 2022
P1, N=275, Recruiting, Sponsor: Amgen
Recruiting --> Active, not recruiting | N=275 --> 170 | Trial completion date: Jul 2025 --> Jul 2026 | Trial primary completion date: Jul 2023 --> Jul 2022 Trial completion date: Feb 2026 --> Jul 2025 | Trial primary completion date: Mar 2024 --> Jul 2023
- || Lumakras (sotorasib) / Amgen
Trial completion date, Monotherapy: CodeBreak101: Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) (clinicaltrials.gov) - Jan 10, 2022
P1b/2, N=1280, Recruiting, Sponsor: Amgen
Trial completion date: Feb 2026 --> Jul 2025 | Trial primary completion date: Mar 2024 --> Jul 2023 Trial completion date: Jan 2026 --> Jan 2027
- | Blincyto (blinatumomab) / Astellas, Amgen, zeluvalimab (AMG 404) / Amgen
Trial completion date, Trial primary completion date, Combination therapy: Blinatumomab in Combination With AMG 404 for the Treatment of Adults With Relapsed or Refractory B Cell Precursor ALL (clinicaltrials.gov) - Dec 7, 2021
P1b, N=27, Recruiting, Sponsor: Amgen
Trial completion date: Jan 2026 --> Jan 2027 Trial completion date: Feb 2023 --> Oct 2023 | Trial primary completion date: Feb 2023 --> Oct 2023
- || zeluvalimab (AMG 404) / Amgen, inezetamab (AMG994) / Amgen
Trial completion date, Trial primary completion date, Combination therapy, Monotherapy, Metastases: Study of AMG 994 Monotherapy and AMG 994 and AMG 404 Combination Therapy in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Nov 29, 2021
P1, N=214, Recruiting, Sponsor: Amgen
Trial completion date: Feb 2023 --> Oct 2023 | Trial primary completion date: Feb 2023 --> Oct 2023 Trial completion date: Oct 2024 --> Aug 2025 | Trial primary completion date: Oct 2024 --> Aug 2025
- | Imdelltra (tarlatamab-dlle) / Amgen, zeluvalimab (AMG 404) / Amgen
Trial primary completion date: AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC) (clinicaltrials.gov) - Nov 3, 2021
P1b, N=50, Recruiting, Sponsor: Amgen
Trial completion date: Oct 2024 --> Aug 2025 | Trial primary completion date: Oct 2024 --> Aug 2025 Trial primary completion date: Mar 2025 --> Mar 2023
- zeluvalimab (AMG 404) / Amgen
Updated results from a phase 1, open-label, multicenter, first-in-human study of AMG 404, a checkpoint inhibitor, in patients with advanced solid tumors (Foyer ABC [VIRTUAL]) - Oct 29, 2021 - Abstract #ESMOIO2021ESMO_IO_249;
P1
Legal entity responsible for the study Amgen Inc. Funding Amgen Inc.
- || Imdelltra (tarlatamab-dlle) / Amgen, zeluvalimab (AMG 404) / Amgen
Enrollment open: AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC) (clinicaltrials.gov) - Oct 6, 2021
P1b, N=50, Recruiting, Sponsor: Amgen
Funding Amgen Inc. Not yet recruiting --> Recruiting